Ability to settle cases influences generic patent challenges, study finds
A white paper suggests that patent case settlements between originator pharmaceutical companies and their generic competitors may be beneficial to drug consumers.
USPTO announces departure of general counsel
The chief legal officer at the United States Patent and Trademark Office has announced he will be leaving.
Leahy demands Myriad “march-in rights”
Senator Patrick Leahy has urged the US National Institutes of Health to force Myriad Genetics to license its patents directed to tests for breast and ovarian cancer.
Ipsen announces acquisition of research partner Syntaxin
On July 15, French pharmaceutical company Ipsen announced it has closed the acquisition of life sciences company and research partner Syntaxin.
US appeals court refuses Arzerra rehearing
Biotechnology company Genmab A/S announced on July 15 that the US Court of Appeals for the Federal Circuit has refused a request to rehear a case related to its Arzerra product.
Glenmark confirms Vimpat challenge
Pharmaceutical company Glenmark Generics has confirmed that it has filed ANDAs with the US FDA to market generic versions of epilepsy drug Vimpat.
IPAB rejects Monsanto plant patent
India’s Intellectual Property Appellate Board has affirmed that US agricultural company Monsanto cannot obtain a patent covering transgenic plants, two years after it was first rejected.
Australian bid for OxyContin generic dismissed
The Federal Court of Australia has dismissed Spirit Pharmaceutical’s bid to introduce a generic version of painkiller OxyContin.
Greenberg Traurig names new IP co-chair in Boston
US law firm Greenberg Traurig has appointed shareholder Jennifer Camacho as co-chair of its Boston IP group.
Myriad sues Ambry over cancer gene screening tests
Biotech company Myriad Genetics has filed a patent infringement case against Ambry Genetic Corp for allegedly infringing 10 patents related to genetic diagnostic testing.
